The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
They are not saying anything about the battery being any lighter for the same energy density, or am I not understanding this properly.
This milestone indicates that Ilika’s Goliath solid-state pouch cell can now match the energy density of traditional lithium-ion pouch cells. EV producers the benefits of solid-state batteries' improved safety, faster charging, longer lifespan, and greater temperature resilience, without the need to sacrifice size, space, or effective range.
The EpiSwitch® platform has reduced to practice all stages of the discovery, development, validation, and monitoring of blood-based biomarkers, based on 3D genome architecture. To date, 3D genomic EpiSwitch® biomarkers, also known as chromosome conformation signatures; have been used in blood test format to stratify melanoma patients; prognostically stratify patients with fast versus slow progressing motor neurone disease; stratify patients with symptomatic and pre-symptomatic neurodegenerative disease; diagnose patients with thyroid cancer and various stages of prostate cancer; prognostically stratify patients for outcome in diffuse large B cell lymphoma; predictively stratify patients with NSCLC for response to the anti-PD-L1 ICI Avelumab; prognostically stratify high-risk individuals with an immune-health profile susceptible to systemic hyperreaction and severe COVID disease complications upon infection with SARS-CoV-2; and significantly increase PSA positive predictive value in the context of prostate cancer treatment in the population at risk
Cyberbud, That's a silly question to ask me! I don't know what other people are thinking, I can only speculate, maybe they don't understand the technology, maybe they are shorting the stock, maybe they want a better entry price, maybe they they don't want a challenge to the PSA test, Who the F.. knows, try contacting OBD and asking them for an explanation.
My understanding why a smaller number only needed in the trial. Many years of research have gone into finding rouge DNA that is the cause of PC. Thousands of blood samples have been taken from unfortunate souls that have suffered PC, they now know pretty much what to look for. The EpiSwitch technology looks at the DNA in 3D, this gives much better detail, making it easier to spot the offending DNA.
OBD has got a history bank of over 15,000 blood samples stored, using their EpiSwitch technology for use in all their product developments
Sorry wrong link in last post, Don't know that happened!
https://www.youtube.com/watch?v=sumCUzZp5yo&t=188s&pp=ygUFaWxpa2E%3D
https://www.youtube.com/watch?v=mCWc9pI89fk&pp=ygUFaWxpa2E%3D
One on youtube as well
https://www.youtube.com/watch?v=c0vpqsczZ-c
Yes Barno, too true.
ilika M-cap is tiny compared to the Goliath sized company's developing solid state, they will be circling/sniffing around tiny ilika for sure, wondering if the tec is better than theirs, or could the IP added to their own battery tec, making a better product! Then you have the Chinese, they would love to have this technology for themselves.
Is this for real! I find this statement unprofessional to the point of damning from a secretary or someone who reply's to emails. " we now need to see this tested in far greater numbers of men before we can determine just how effective this approach could be" I thought the idea of the trial was to test on a large number of men to determine what worked best!
Wireless charging, yes another new innovation for medical battery implants, should think though, the technology would be available for all manufacturers to make the most of, smart phones have been using it for a long time. I have noticed though, the battery and charger need to be quite close together for it to work, as they do with s- phones, with a car battery and wireless charging, the car wheels are going to elevate the battery, making the deign for a charger more challenging, then you have to look a the time it takes to charge, it will take longer, something you don't want if stopping for a charge on a longish journey
Cancer Research could end up looking very foolish if the new PSE test is not included, could say a big opportunity wasted, spending time and money gathering data on outdated technology would be mistake IMO.
The PSE test is designed to run alongside a standard PSA test, and combines the PSA score with five proprietary epigenetic biomarkers to predict, with 94% accuracy, the presence (or absence) of prostate cancer.2 Those with a PSE result of low likelihood of cancer can be placed on active surveillance and retested later without being referred for an invasive and often destructive biopsy. A high likelihood result would necessitate referral to a Urologist for further investigation. As well as very high accuracy, PSE has high specificity of 97% (PSA: 53%) and sensitivity of 86% (PSA: 64%), along with both high positive, 93% (PSA: 25%), and high negative, 95% (PSA: 86%), predictive values to assess the risk of prostate cancer in men.2 It has been validated as a laboratory developed test (LDT) in OBD's CLIA-certified testing laboratory in Frederick, Maryland.